November 25, 2019
1 min read

CD22 Redirected Autologous T Cells for ALL

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Phase 1, single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-zeta and 4-1BB (TCR-zeta/4-1BB) co-stimulatory domains (referred to as “CART22” cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.